{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:03:20Z","timestamp":1790035400847,"version":"4.0.1"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","award":["P30CA016058"],"award-info":[{"award-number":["P30CA016058"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients with locally advanced or metastatic cutaneous squamous cell carcinoma (cSCC), who failed cemiplimab, have a poor prognosis, with most patients dying of disease. Second-line therapies consist of additional immunotherapy, epidermal growth factor receptor (EGFR) inhibitors, chemotherapy, salvage surgery, or radiotherapy. Outcomes in this setting remain poorly characterized. We review the first 2 options for our population. The study objective was to describe non-clinical-trial\/off-label immunotherapy treatments for advanced, recurrent, or refractory cSCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients<\/jats:title>\n                    <jats:p>This single-institution retrospective case series took place at The Ohio State University Comprehensive Cancer Center, a high-volume academic medical oncology practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We reviewed the electronic medical records of patients who underwent systemic treatments for advanced cSCC. Patient demographics, clinicopathologic history, cancer data, treatments, and outcomes were abstracted. Overall response and progression-free survival by clinical judgment and overall survival rates were described.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 21 patients were included. Thirteen received cetuximab and 12 ipilimumab after failure of surgery and\/or radiation, and of a programmed cell death protein 1 (PD-1) monoclonal inhibitor (primarily cemiplimab). Four patients are included in both cohorts. Durable complete responses were observed only in patients treated with ipilimumab. Otherwise, all other surviving patients had salvage surgery after some response to second line therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this salvage setting, ipilimumab demonstrated a 33% response rate, including complete responses with durable survival. Cetuximab induced response in patients pretreated with cemiplimab whether they had responded or not to this immunotherapy. Most cetuximab-treated patients died within 1-2\u2009years, unless salvaged with surgery.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag038","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T12:34:37Z","timestamp":1770726877000},"source":"Crossref","is-referenced-by-count":2,"title":["Second-line treatments for patients with programmed cell death protein 1-refractory cutaneous squamous cell carcinomas: a brief report"],"prefix":"10.1093","volume":"31","author":[{"given":"Hisham","family":"AlSharif","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center , Columbus, OH 43210,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Danchine","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center , Columbus, OH 43210,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kira","family":"Deekollu","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center , Columbus, OH 43210,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merve","family":"Hasanov","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center , Columbus, OH 43210,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Wu","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center , Columbus, OH 43210,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek","family":"Haykal","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center , Columbus, OH 43210,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Faieta","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center , Columbus, OH 43210,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6544-3089","authenticated-orcid":false,"given":"Claire F","family":"Verschraegen","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center , Columbus, OH 43210,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"key":"2026031316365740800_oyag038-B1","doi-asserted-by":"publisher","first-page":"606","DOI":"10.3390\/cancers16030606","article-title":"Epidemiology of keratinocyte skin cancer with a focus on cutaneous squamous cell carcinoma","volume":"16","author":"Nanz","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2026031316365740800_oyag038-B2","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1001\/jamadermatol.2015.1187","article-title":"Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the U.S. population, 2012","volume":"151","author":"Rogers","year":"2015","journal-title":"JAMA Dermatol"},{"key":"2026031316365740800_oyag038-B3","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/jdv.15967","article-title":"Incidence and mortality for cutaneous squamous cell carcinoma: comparison across three continents","volume":"33","author":"Stang","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026031316365740800_oyag038-B4","doi-asserted-by":"publisher","first-page":"550","DOI":"10.3390\/cancers14030550","article-title":"Recent advanced in the treatment of advanced SCC tumors","volume":"14","author":"Basset-Seguin","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2026031316365740800_oyag038-B5","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1097\/CCO.0000000000000566","article-title":"Advanced cutaneous squamous cell carcinoma: how is it defined and what new therapeutic approaches are available?","volume":"31","author":"Soura","year":"2019","journal-title":"Curr Opin Oncol"},{"key":"2026031316365740800_oyag038-B6","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1056\/NEJMoa2502449","article-title":"Adjuvant cemiplimab or placebo in high-risk cutaneous squamous-cell carcinoma","volume":"393","author":"Rischin","year":"2025","journal-title":"N Engl J Med"},{"key":"2026031316365740800_oyag038-B7","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jaad.2024.06.108","article-title":"A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6","volume":"92","author":"Hughes","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"2026031316365740800_oyag038-B8","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1080\/17512433.2019.1665026","article-title":"Cemiplimab-rwlc as first and only treatment for advanced cutaneous squamous cell carcinoma","volume":"12","author":"Ahmed","year":"2019","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2026031316365740800_oyag038-B9","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.2147\/CCID.S381471","article-title":"Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma: appropriate patient selection and perspectives","volume":"16","author":"Mager","year":"2023","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"2026031316365740800_oyag038-B10","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1056\/NEJMoa2209813","article-title":"Neoadjuvant cemiplimab for stage II to IV cutaneous squamous-cell carcinoma","volume":"387","author":"Gross","year":"2022","journal-title":"N Engl J Med"},{"key":"2026031316365740800_oyag038-B11","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.annonc.2021.07.008","article-title":"Pembrolizumab for locally advanced and recurrent\/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial","volume":"32","author":"Hughes","year":"2021","journal-title":"Ann Oncol"},{"key":"2026031316365740800_oyag038-B12","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jaad.2025.09.009","article-title":"Efficacy and safety of cosibelimab in advanced cutaneous squamous cell carcinoma: results from a pivotal open-label study with a median follow-up of \u22652 years","volume":"94","author":"Ruiz","year":"2026","journal-title":"J Am Acad Dermatol"},{"key":"2026031316365740800_oyag038-B13","author":"National Comprehensive Cancer Network","year":"2024"},{"key":"2026031316365740800_oyag038-B14","doi-asserted-by":"publisher","first-page":"e000775","DOI":"10.1136\/jitc-2020-000775","article-title":"Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing","volume":"8","author":"Rischin","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026031316365740800_oyag038-B15","doi-asserted-by":"publisher","first-page":"e007637","DOI":"10.1136\/jitc-2023-007637","article-title":"Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma","volume":"11","author":"Clingan","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2026031316365740800_oyag038-B16","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1097\/CAD.0b013e328358d226","article-title":"Efficacy and safety of capecitabine in heavily pretreated recurrent\/metastatic head and neck squamous cell carcinoma","volume":"23","author":"P\u00e9ron","year":"2012","journal-title":"Anticancer Drugs"},{"key":"2026031316365740800_oyag038-B17","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1038\/sj.bjc.6605697","article-title":"Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment","volume":"102","author":"Martinez-Trufero","year":"2010","journal-title":"Br J Cancer"},{"key":"2026031316365740800_oyag038-B18","doi-asserted-by":"publisher","first-page":"4223","DOI":"10.1002\/cncr.34463","article-title":"A phase 2 study of first-line nivolumab in patients with locally advanced or metastatic cutaneous squamous-cell carcinoma","volume":"128","author":"Munhoz","year":"2022","journal-title":"Cancer"},{"key":"2026031316365740800_oyag038-B19","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1200\/JCO.1990.8.2.342","article-title":"Cisplatin-based chemotherapy in advanced basal and squamous cell carcinomas of the skin: results in 28 patients including 13 patients receiving multimodality therapy","volume":"8","author":"Guthrie","year":"1990","journal-title":"J Clin Oncol"},{"key":"2026031316365740800_oyag038-B20","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/CAD.0b013e328325a9d7","article-title":"A phase II study of carboplatin and paclitaxel for recurrent or metastatic head and neck cancer","volume":"20","author":"Ferrari","year":"2009","journal-title":"Anticancer Drugs"},{"key":"2026031316365740800_oyag038-B21","doi-asserted-by":"publisher","first-page":"714551","DOI":"10.3389\/fonc.2021.714551","article-title":"Weekly paclitaxel, carboplatin, and cetuximab as first-line treatment of recurrent and\/or metastatic head and neck squamous cell carcinoma for patients ineligible to cisplatin-based chemotherapy: a retrospective monocentric study in 60 patients","volume":"11","author":"Carinato","year":"2021","journal-title":"Front Oncol"},{"key":"2026031316365740800_oyag038-B22","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1186\/s12967-021-02975-3","article-title":"Weekly chemotherapy as first line treatment in frail head and neck cancer patients in the immunotherapy era","volume":"19","author":"Botticelli","year":"2021","journal-title":"J Transl Med"},{"key":"2026031316365740800_oyag038-B23","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1093\/annonc\/mdy040","article-title":"Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and\/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02)","volume":"29","author":"Tahara","year":"2018","journal-title":"Ann Oncol"},{"key":"2026031316365740800_oyag038-B24","doi-asserted-by":"publisher","first-page":"240","DOI":"10.3892\/mco.2021.2403","article-title":"Weekly vs. 3-weekly paclitaxel, carboplatin, and cetuximab (PCC) in recurrent\/metastatic head and neck cancer","volume":"15","author":"Geraghty","year":"2021","journal-title":"Mol Clin Oncol"},{"key":"2026031316365740800_oyag038-B25","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1002\/1097-0142(19910415)67:8&lt;2030::aid-cncr2820670803&gt;3.0.co;2-k","article-title":"Cisplatin and 5-fluorouracil for advanced locoregional and metastatic squamous cell carcinoma of the skin","volume":"67","author":"Khansur","year":"1991","journal-title":"Cancer"},{"key":"2026031316365740800_oyag038-B26","doi-asserted-by":"publisher","first-page":"3419","DOI":"10.1200\/JCO.2010.34.1735","article-title":"Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin","volume":"29","author":"Maubec","year":"2011","journal-title":"J Clin Oncol"},{"key":"2026031316365740800_oyag038-B27","doi-asserted-by":"publisher","first-page":"3180","DOI":"10.3390\/cancers15123180","article-title":"Cetuximab for immunotherapy-refractory\/ineligible cutaneous squamous cell carcinoma","volume":"15","author":"Marin-Acevedo","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026031316365740800_oyag038-B28","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1159\/000362384","article-title":"Cetuximab in metastatic squamous cell cancer of the skin: a Swiss case series","volume":"229","author":"Conen","year":"2014","journal-title":"Dermatology"},{"key":"2026031316365740800_oyag038-B29","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1097\/DSS.0000000000001755","article-title":"Cetuximab as a component of multimodality treatment of high-risk cutaneous squamous cell carcinoma: a retrospective analysis from a single tertiary academic medical center","volume":"45","author":"Trodello","year":"2019","journal-title":"Dermatol Surg"},{"key":"2026031316365740800_oyag038-B30","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1001\/archderm.143.7.889","article-title":"Treatment of recurrent squamous cell carcinoma of the skin with cetuximab","volume":"143","author":"Bauman","year":"2007","journal-title":"Arch Dermatol"},{"key":"2026031316365740800_oyag038-B31","doi-asserted-by":"publisher","first-page":"257","DOI":"10.7150\/jca.3491","article-title":"Cetuximab in refractory skin cancer treatment","volume":"3","author":"Kalapurakal","year":"2012","journal-title":"J Cancer"},{"key":"2026031316365740800_oyag038-B32","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1080\/14728214.2023.2208345","article-title":"New and emerging drugs for the treatment of advanced cutaneous squamous cell carcinoma","volume":"28","author":"Bonini","year":"2023","journal-title":"Expert Opin Emerg Drugs"},{"key":"2026031316365740800_oyag038-B33","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/jdv.16024","article-title":"Medical treatment of advanced cutaneous squamous-cell carcinoma","volume":"33","author":"Gellrich","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026031316365740800_oyag038-B34","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1097\/CJI.0000000000000146","article-title":"Durable response of metastatic squamous cell carcinoma of the skin to ipilimumab immunotherapy","volume":"40","author":"Day","year":"2017","journal-title":"J Immunother"},{"key":"2026031316365740800_oyag038-B35","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1805131","article-title":"PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma","volume":"379","author":"Migden","year":"2018","journal-title":"N Engl J Med"},{"key":"2026031316365740800_oyag038-B36","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1200\/JCO.19.03054","article-title":"Pembrolizumab monotherapy for recurrent or metastatic cutaneous squamous cell carcinoma: a single-arm phase II trial (KEYNOTE-629)","volume":"38","author":"Grob","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026031316365740800_oyag038-B37","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1200\/JCO.23.01497","article-title":"Nivolumab + tacrolimus + prednisone \u00b1 ipilimumab for kidney transplant recipients with advanced cutaneous cancers","volume":"42","author":"Schenk","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026031316365740800_oyag038-B38","doi-asserted-by":"publisher","first-page":"115379","DOI":"10.1016\/j.ejca.2025.115379","article-title":"Immunotherapy followed by cetuximab in locally advanced\/metastatic cutaneous squamous cell carcinomas: the I-TACKLE trial","volume":"220","author":"Bossi","year":"2025","journal-title":"Eur J Cancer"},{"key":"2026031316365740800_oyag038-B39","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1200\/JCO-25-00759","article-title":"Phase II (alliance A091802) randomized trial of avelumab plus cetuximab versus avelumab alone in advanced cutaneous squamous cell carcinoma","volume":"43","author":"Zandberg","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag038\/66921479\/oyag038.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/4\/oyag038\/66921479\/oyag038.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/4\/oyag038\/66921479\/oyag038.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T20:37:06Z","timestamp":1773434226000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag038\/8487205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,3,9]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag038","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2026,2,16]]},"article-number":"oyag038"}}